Angiodynamics, Inc. ( (ANGO) ) has released its Q4 earnings. Here is a breakdown of the information Angiodynamics, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AngioDynamics, Inc. is a leading medical technology company specializing in innovative solutions for vascular health, cancer treatment, and improving patient quality of life. The company operates primarily in the MedTech industry, focusing on transformative technologies that address unmet medical needs.
AngioDynamics recently reported strong financial results for the fourth quarter and full fiscal year 2025, highlighting significant revenue growth and operational efficiency. The company achieved over 20% revenue growth in its MedTech franchise for the third consecutive quarter, alongside positive adjusted EBITDA for the full year.
Key financial highlights include a 12.7% increase in net sales for the fourth quarter, reaching $80.2 million, and a 22.0% growth in MedTech net sales. The company’s gross margin was impacted by tariffs but remained robust at 52.7%. Despite a GAAP net loss, AngioDynamics reported a pro forma adjusted EBITDA of $3.4 million for the quarter. The company also expanded its financial flexibility with a $25 million revolving credit facility.
Looking ahead, AngioDynamics is well-positioned for continued growth, with management expressing confidence in the company’s strategic transformation and market opportunities. The company aims to capitalize on its innovative platform technologies and regulatory milestones to drive further value creation in fiscal 2026.